Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in New York: - Northwell Health Imbert Cancer Center — Bay Shore, New York
- New York-Presbyterian Westchester Hospital — Bronxville, New York
- New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in New York: - Northwell Health Imbert Cancer Center — Bay Shore, New York
- NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Glens Falls Hospital — Glens Falls, New York
- Northwell Health Cancer Institute at Huntington — Greenlawn, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
Phase 3 Recruiting NIH
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06058377
Sites in New York: - NYU Langone Hospital - Brooklyn — Brooklyn, New York
- The Cancer Institute at Saint Francis Hospital — East Hills, New York
- Glens Falls Hospital — Glens Falls, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- Northern Westchester Hospital — Mount Kisco, New York
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in New York: - NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- Mount Sinai Chelsea — New York, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in New York: - New York Oncology Hematology (NYOH) — Amsterdam, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Hematology Oncology Associates of Central New York, PC — East Syracuse, New York
- Northwell Health — Lake Success, New York
- Laura and Isaac Perlmutter Cancer Canter — New York, New York
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…
Sponsor: AstraZeneca
NCT ID: NCT05774951
Sites in New York: - Research Site — East Syracuse, New York
- Research Site — New Hyde Park, New York
- Research Site — New York, New York
- Research Site — New York, New York
- Research Site — New York, New York
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in New York: - New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Babylon) — Babylon, New York
- NYU Langone's Perlmutter Cancer Center — Manhattan, New York
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C.(New Hyde Park) — New Hyde Park, New York
- Manhattan Hematology /Oncology Associates — New York, New York
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C (NY) — New York, New York
Phase 3 Recruiting Industry
This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participant…
Sponsor: BioNTech SE
NCT ID: NCT07173751
Sites in New York: - Paradigm New York Cancer and Blood Specialists — Bay Shore, New York
- Paradigm New York Cancer and Blood Specialists — New York, New York
- Paradigm New York Cancer and Blood Specialists — New York, New York
- Paradigm New York Cancer and Blood Specialists — New York, New York
- Paradigm New York Cancer and Blood Specialists — New York, New York
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in New York: - Research Site — Albany, New York
- Research Site — New York, New York
- Research Site — Stony Brook, New York
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in New York: - The Blavatnik Family ? Chelsea Medical Center at Mount Sinai — New York, New York
- Mount Sinai West — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- New York Cancer & Blood Specialists — Shirley, New York
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in New York: - Clinical Trial Site — New York, New York
- Clinical Trial Site — New York, New York
Phase 3 Recruiting Industry
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…
Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in New York: - Research Site — Brooklyn, New York
- Research Site — Mineola, New York
- Research Site — New Hyde Park, New York
- Research Site — New York, New York
- Research Site — New York, New York
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in New York: - Laura and Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Columbia University Irving Medical Center — New York, New York
- Memorial Sloan-Kettering Cancer Center — New York, New York
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in New York: - New York Oncology Hematology — Albany, New York
- New York-Presbyterian - Columbia University Irving Medical Center — New York, New York
- Stony Brook University Cancer Center — Stony Brook, New York
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in New York: - Memorial Sloan Kettering — Long Island City, New York
- Perlmutter Cancer Center 160 E 34th St — New York, New York
- The Mount Sinai Hospital — New York, New York
- Columbia University Medical Center 161 Fort Washington — New York, New York
Phase 3 Recruiting Industry
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in New York: - NYU Langone Health - Brooklyn ( Site 0089) — Brooklyn, New York
- NYU Langone Hospital - Long Island ( Site 0090) — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center-Hematology and Oncology ( Site 0068) — New York, New York
- Hematology Oncology Associates of Rockland ( Site 0054) — Nyack, New York
- Stony Brook University-Cancer Center ( Site 0034) — Stony Brook, New York
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in New York: - Local Institution - 0312 — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Local Institution - 1037 — Syracuse, New York
- Clinical Research Alliance — Westbury, New York
- White Plains Hospital — White Plains, New York
Phase 3 Recruiting Industry
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…
Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in New York: - The Blavatnik Family - Chelsea Medical Center at Mount Sinai — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (H…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07060807
Sites in New York: - Queens Hospital Cancer Center ( Site 0011) — Jamaica, New York
- Optum Medical Care, PC ( Site 0009) — Westbury, New York
Phase 3 Recruiting Industry
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast …
Sponsor: Celcuity Inc
NCT ID: NCT06757634
Sites in New York: - Weill Cornell Medical College - NewYork-Presbyterian Hospital — New York, New York
- Clinical Research Alliance, Inc. — Westbury, New York
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.
Sponsor: Hoffmann-La Roche
NCT ID: NCT07413939
Sites in New York: - New York Oncology Hematology, P.C. — Albany, New York
- New York Cancer and Blood Specialists — Shirley, New York
- Stony Brook Univ Cancer Ctr — Stony Brook, New York
- Montefiore Einstein Cancer Center — The Bronx, New York
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 2 Recruiting Academic/Other
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in New York: - New York University Langone Hospital -Brooklyn — Brooklyn, New York
- New York University Langone Hospital - Long Island — Mineola, New York
- New York University Langone Health — New York, New York
- Northwell University — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in New York: - Northwell Health — Lake Success, New York
- Laura & Isaac Perlmutter Cancer Center at NYC Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- North Shore Hematology Oncology Associate P.C. DBA New York Cancer and Blood Specialists — Shirley, New York
Phase 2 Recruiting Industry
This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant…
Sponsor: Eli Lilly and Company
NCT ID: NCT07287098
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
- Wilmot Cancer Institute — Rochester, New York
- New York Cancer and Blood Specialists — Shirley, New York